GlassScriptPhysician profile
Irfan Idrees
NPI 1134171218
$1,474.75
in general payments reported to CMS, 2019-2025
23 companies · $206 in 2025
The $206 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $383 · 2020: $119 · 2021: $459 · 2022: $94.36 · 2023: $78.89 · 2024: $134 · 2025: $206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $419.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $418.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $349.64 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $210.23 | 2021-2025 | |
| Pfizer INC. | $108.79 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $94.75 | 2019-2025 | Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $83.83 | 2019-2025 | Xifaxan |
| Amarin Pharma, INC. | $64.42 | 2019-2021 | |
| Glaxosmithkline, LLC. | $60.52 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Verona Pharma, INC. | $56.46 | 2025 | Ohtuvayre |
| Amgen INC. | $52.57 | 2024 | Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $48.64 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $43.40 | 2019 | |
| Allergan, INC. | $36.30 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.76 | 2021 | |
| Supernus Pharmaceuticals, INC. | $35.55 | 2019 | |
| Janssen Pharmaceuticals, INC | $31.85 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $28.80 | 2019 | |
| Cmp Pharma, INC. | $27.69 | 2020 | |
| Genentech USA, INC. | $26.64 | 2019-2020 | |
| Esperion Therapeutics, INC. | $17.98 | 2020 | |
| Abbott Laboratories | $16.83 | 2023 | Freestyle Libre 3 |
| Orexo US, INC. | $15.58 | 2021 | |
| Amneal Pharmaceuticals LLC | $14.77 | 2024 | Unithroid |
| Exact Sciences Corporation | $13.75 | 2025 | The Cologuard Plus Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irfan Idrees listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.